Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Pan-Cancer Project looks closer, sees more

Feb. 7, 2020

Phase I results for troriluzole plus nivolumab in patients advanced or refractory solid tumors

Feb. 7, 2020

Tau keeps gliomas in check

Feb. 7, 2020

Lamivudine shows promising safety and activity in p53 mutant mCRC

Feb. 6, 2020

TUSC2 as a novel therapeutic target in thyroid carcinoma

Feb. 6, 2020

Commercial antibodies underwhelm for studies of PP2A

Feb. 6, 2020

Medshine Discovery synthesizes new FGFR and HGFR inhibitors

Feb. 5, 2020

Phase I/II data presented for Pexa-Vec plus durvalumab in CRC

Feb. 5, 2020

B4GALNT1 and its products GM2/GD2 enhance tumorigenesis in melanoma by inducing angiogenesis

Feb. 4, 2020

Nanoparticle monotherapy effective in HER2+ breast cancer in mice

Feb. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...